Genedrive partnered with Thermo Fisher Scientific to develop a CYP2C19 pharmacogenetic in vitro diagnostic kit designed for Thermo Fisher’s QuantStudio 5 Dx platform. The test targets clopidogrel poor metabolizers and is aligned with UK National Institute for Health and Care Excellence recommendations for ischemic stroke or transient ischemic attack patients. Genedrive said the CYP2C19 HT kit will use multiplexed PCR to increase sample throughput per run and will be configured for an ambient, lyophilized workflow that can test blood samples without a nucleic acid extraction step. Initial commercialization focus is the UK NHS genomic laboratory market. Thermo Fisher’s installed base and QuantStudio ecosystem could accelerate adoption compared with bespoke assays, while the design choices target operational complexity and consumable use in high-throughput settings.